CJC-1295 and sermorelin are both GHRH analogues — synthetic versions of the hormone that tells the pituitary to release growth hormone. The core difference is duration: sermorelin mirrors the natural hormone and is cleared within minutes, while CJC-1295 was engineered for a multi-day half-life. Sermorelin also has the unusual distinction of having once been an approved medicine (Geref, since discontinued), while CJC-1295 has only early-phase human data.
| Attribute | CJC-1295 | Sermorelin |
|---|---|---|
| Class | Long-acting GHRH analogue (GRF 1-29 with DAC modification) | GHRH analogue (GRF 1-29, matches the natural sequence) |
| Half-life | Days (albumin-binding DAC extends clearance) | Minutes — mimics the natural GHRH pulse |
| Human data | Early-phase studies: elevated GH/IGF-1 for days after single doses (JCEM 2006) | Clinical history as an approved product; diagnostic and paediatric GH-deficiency use |
| Regulatory status | Investigational — never approved | Formerly approved (Geref); withdrawn from market, no current authorisation |
| GH release pattern | Sustained elevation — flattens the natural pulse | Pulse-preserving — brief stimulation like the endogenous rhythm |
| WADA status | Prohibited | Prohibited |
| In the Body Pharm catalogue | Yes — combined with Ipamorelin | No |
Sermorelin behaves like the hormone it copies: a brief signal that works with the body’s pulsatile GH rhythm and is gone in minutes. CJC-1295’s DAC modification binds albumin and stretches that signal across days — the property demonstrated in its 2006 human pharmacology studies. Whether a sustained elevation or a preserved pulse is preferable is a genuinely open research question: the pulse is how GH physiology naturally operates, while sustained elevation produces larger cumulative IGF-1 exposure.
Sermorelin was an approved medicine — marketed as Geref for growth-hormone deficiency — before being discontinued for commercial reasons, so its human safety record comes from real clinical use. CJC-1295 never progressed past early-phase studies. Neither is an authorised medicine today, and both sit on the WADA prohibited list.
GHRH analogues amplify the GH pulse; secretagogues like ipamorelin trigger it through a second receptor (the ghrelin receptor). The pairing hypothesis — amplify and trigger together — is why CJC-1295/Ipamorelin became the standard research combination, and it is the format Body Pharm supplies. Sermorelin research uses the same logic when paired with GHRP-class compounds.
It is longer-acting rather than "stronger" — single doses elevated GH and IGF-1 for days in human studies, versus minutes of activity for sermorelin. Sustained exposure and pulse-preserving stimulation are different research profiles, not a simple potency ranking.
Yes — sermorelin was marketed as Geref for growth-hormone deficiency before being discontinued. No GHRH analogue in this comparison holds a current marketing authorisation.
CJC-1295 combined with Ipamorelin in a pre-loaded research pen. Sermorelin is not in the catalogue.
No — GHRH analogues and GH secretagogues are prohibited at all times under WADA.
This page is educational and intended for research and informational use only. It is not medical advice, a treatment recommendation, or dosing guidance, and it makes no promises about outcomes. Where a compound has held a marketing authorisation, approved medicines are supplied only through licensed pharmacies with a prescription. Body Pharm EU supplies research-grade materials for laboratory use, not approved medicines, and nothing here should be read as a substitute for advice from a qualified healthcare professional.
We use cookies for analytics and marketing to improve your experience. You can accept or reject non-essential cookies. Privacy Policy